The participation of L-selectin in leukocyte recruitment during inflammation has suggested the use of L-selectin inhibitors as potential anti-inflammatory therapeutics. Blocking monoclonal antibodies could serve as such therapeutic agents. The mouse monoclonal antibody, DREG-200, that block human L-selectin.
Figure 1 Competition of radiolabeled antibodies with mouse and humanized DREG-55 (A) or DREG-200 (B).
Each point shows the average of duplicate samples.
Figure 2 Binding of polymerized liposomes containing sialyl Lewis X to peripheral blood lymphocytes and neutrophils in the presence of anti-L-selectin antibodies.
Following a 1h incubation and washing, cells were evaluated by flow cytometry with a Becton Dickinson FACScan using FL3.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-2242-VHH | Recombinant Anti-Human SELL VHH Single Domain Antibody | Neut, ChiP, IP, FUNC | Llama VHH |
There are currently no Customer reviews or questions for FAMAB-0209YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.